Browse Articles
Discover research articles across all indexed journals
Synthesis and characterization of selenium-containing sodium phosphate glasses with enhanced physical and radiation shielding performance
Training set augmentation and biology-aware harmonization improve radiomic models for lung cancer prediction in indeterminate nodules
Abstract CT radiomics-based machine learning has potential to predict lung cancer in pulmonary nodules (PNs) earlier than standard-of-care methods. Low malignancy rates in early-development PNs and variable image acquisition hinder development of radiomic models for diagnosing these PNs. To address these challenges, we augmented training using later-development PNs and harmonized for acquisition effects. We examine early-development benign and malignant PNs (n = 106) below the sensitivity of standard-of-care diagnosis. Classifiers predicting malignancy performed near chance when trained on ComBat-harmonized radiomic features from only early-development PNs. We then augmented training with later-development benign and malignant PNs (n = 225). We evaluated whether harmonization must incorporate biology that impacts acquisition effects in added training data. To correct variability from four acquisition protocols, we compared: (1) biology-unaware harmonization, (2) harmonizing with a covariate distinguishing early-development, later-development benign, later-development malignant datasets, (3) harmonizing each dataset separately. Models trained using augmentation, but biology-unaware harmonization, failed to improve consistently. Augmented training data harmonized with a covariate (ROC-AUC 0.74 [0.69–0.79]) or separately (ROC-AUC 0.71 [0.66–0.77]) yielded higher test ROC-AUC (Delong, p ≤ 0.05) and PR-AUC (Wilcoxon, p ≤ 0.05). In a proof-of-principle methodological study, we demonstrate with a small single-center dataset that combining radiomic features from later-development benign and malignant PNs requires biology-aware harmonization.
DFT studies of doped and encapsulated of B12N12 nanocage using nickel and platinum metals as carriers for Sunvozertinib drug
Social inequality and the mental health of Chinese youth
EMG-based hand gesture recognition using multi-scale deep residual network with SE-module
Solidago canadensis extract fractionation, phytochemical identification, and nematicidal/nematistatic activity against Meloidogyne incognita
Abstract The development of eco-friendly pest management strategies is crucial for sustainable agriculture. In this study, we investigated the bioactivity of Solidago canadensis leaf extract against Meloidogyne incognita juveniles (J2). In vitro assays showed that aqueous extracts exhibited greater nematistatic (immobilizing) activity than less polar solvent extracts. Fractionation of the aqueous decoction extract using column chromatography yielded 11 fractions (F), which were evaluated at 100, 200, and 300 mg L − 1 . The crude extract showed 100% nematistatic activity at all concentrations, while among the fractions, F5, F7, and F9 were the most effective. In the pot experiment, the crude extract and F7 reduced gall formation by 55.3%, whereas F8, despite low in vitro nematistatic activity (21.5%), achieved the highest gall reduction (58.7%). Unexpectedly, some fractions increased gall formation. GC-MS analysis of F7 and F8 revealed 20 phytochemical compounds, including several with reported nematode-suppressive properties. These findings underscore the potential of S. canadensis extracts and specific fractions as botanical nematistatic agents and emphasize the importance of combining the in vitro and pot bioassays when evaluating botanical nematicides.
The impact of Paulownia–buckwheat intercropping on the biodiversity of different living biota
Abstract Intercropping has emerged as a promising strategy to improve agroecosystem biodiversity and mitigate some adverse effects associated with intensive monoculture systems. This study evaluated weed infestation and biodiversity responses in a Paulownia –buckwheat intercropping system compared with buckwheat monoculture under the environmental conditions of southwestern Poland. Weed species composition, abundance, and biomass were assessed at different growth stages of buckwheat. Selected agroecosystem components, including soil microorganisms, soil mesofauna, and pollinator abundance, were evaluated. The intercropping system increased Collembola diversity and Acari abundance, while higher diversity and richness of segetal plant species were also observed compared with monoculture. Higher bacterial abundance and dehydrogenase activity were recorded under intercropping, whereas fungal community composition remained generally stable between cultivation systems. Several melliferous weed species were identified within the intercropping system, potentially supporting pollinator activity. Although no statistically significant differences were observed in pollinator-related parameters, nectar productivity and sugar availability tended to be higher under intercropping conditions, suggesting that the Paulownia –buckwheat system may contribute to maintaining pollinator activity and supporting agroecosystem biodiversity. No significant differences in buckwheat yield or biometric traits were found between cultivation systems. Overall, the results indicate that Paulownia –buckwheat intercropping may enhance selected components of agroecosystem biodiversity without reducing crop productivity.
Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
Design of a Fano-resonance-enhanced dielectric grating for ultralow-filling-factor superconducting nanowire single-photon detector
Abstract Superconducting nanowire single photon detectors (SNSPDs) exhibit excellent performance in the near-infrared band, but their application range is limited by the detection efficiency and detection speed. In this paper, we propose a high-efficient and ultralow-filling-factor design scheme based on Fano resonance which is excited by a one-dimensional silicon dielectric grating. This design can reduce the kinetic inductance of the nanowires while maintaining the active sensing area of SNSPDs, which is beneficial for improving the recovery time of the detector. Meanwhile, the absorption efficiency of the nanowires can be enhanced by the Fano resonance. Taking λ = 1550 nm as an example, numerical simulations are performed using commercial simulation software based on the finite-difference time-domain method. Under idealized structural conditions, the absorption efficiency of the Niobium Nitride (NbN) superconducting nanowires can exceed 98% when the filling factor of the nanowire is only 10%.
Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS
Effects of anchor characteristics and product attributes on consumer purchase decisions in live streaming sales: evidence from an eye-tracking study
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
A dual track predictive model for assessing crow’s feet aging across different clinical severity grades
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy
The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to expand and the rising global incidence results in an increasing number of diagnoses within the pregnant population, there is a pressing need to gain a deeper understanding of the potential options for pregnant women and the impact on the newborn. As knowledge of the effects of cancer treatment increases, more women are receiving adequate cancer diagnosis and treatment during pregnancy. This paper presents an expert opinion on the use of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for acute leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloproliferative neoplasms, aplastic anemia, and multiple myeloma during pregnancy.
Multi-criteria-based determination of optimal probability distribution with four parameter estimation methods using wind speed data from ten tropical sites in the South Pacific
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Microscale bioturbation as a first order control on distal prodelta to offshore mudrock reservoirs
Cracks in the Estrogen Carcinogenesis of Breast Cancer
Structure-aware acoustic scene classification: a feature decoupling framework using HPSS and asymmetric convolutions
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
PURPOSE Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particularly those with human papillomavirus (HPV)–negative disease, in which elevated epidermal growth factor receptor and transforming growth factor-β impair tumor penetration of immune cells and lessen immunotherapy responses. METHODS We present results from an expansion cohort of a first-in-human phase I/Ib trial (ClinicalTrials.gov identifier: NCT04429542 ) evaluating first-line treatment with ficerafusp alfa 1,500 mg once every week in combination with pembrolizumab 200 mg once every 3 weeks administered intravenously in patients with R/M HNSCC overexpressing PD-L1 (combined positive score ≥1). The primary end point was safety. Secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS). RESULTS Between February 2022 and April 2023, 42 patients received ≥1 dose of study drug and 39 were included in the efficacy-evaluable set (≥1 postbaseline scan). The median follow-up was 26.3 months. Nineteen of 42 patients (45%) had a grade 3 treatment-related adverse event (TRAE), and one (2%) had a grade 4 TRAE. The most common grade ≥3 TRAEs were anemia (14%) and acneiform dermatitis (12%). In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors, confirmed ORRs were 54% (complete response in 21%) and 27%, respectively. In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]), median PFS was 9.9 months (95% CI, 4.4 to 22.7), and median OS was 21.3 months (95% CI, 9.9 to NE). CONCLUSION Ficerafusp alfa plus pembrolizumab demonstrated favorable safety and tolerability with promising antitumor activity in the first-line treatment of R/M HNSCC, particularly in those with HPV-negative tumors.